UBcare. Co (032620) Fair Value & Analysis
Technology · KR · Market cap 161B KRW
Fair value as of: Jul 6, 2026
From 24 valuation models · updated today
Share price −9.8% over the past month.
Price vs Fair Value (12 months)
12‑month range 2,680 KRW – 4,330 KRW · fair‑value band 4,940 KRW – 15,438 KRW · the 2,915 KRW price screens below the 8,936 KRW fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
UBcare. Co (032620) currently trades at 2,915 KRW, while our model-based Fair Value estimate is 8,936 KRW — implying the stock looks roughly 206.6% undervalued today. We read business quality at 48/100 (below-average quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, UBcare. Co generated revenue of 128B KRW at a net margin of 5.2%. Revenue grew 28.7% year over year. It earns a return on equity of 116.1%. Fundamentals as of Jul 6, 2026
Our scenario range runs from 4,940 KRW (bear case) to 15,438 KRW (bull case); at 2,915 KRW, the current price sits below that range. The share trades about 34% below its 52-week high, currently below its 200-day average. For context, the median of 10 Technology peers we cover trades at 73% fair-value upside — at 207%, 032620 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
UBcare. Co., Ltd. provides health care solutions in South Korea and internationally. The company offers medical IT services, such as Ysarang, an EMR system for hospital/clinic use; and U Pharm, an integrated management control system for pharmacies, hospitals, clinics, and pharmacy environments; and Big Ysarang, an EMR system for small and medium-sized hospitals, as well as customer management and media services. It is also involved in the medical distribution business that suggests products and services, such as high-technology medical equipment/devices for hospitals, clinics, pharmacies, medical e-commerce businesses, and shop-in-shop for health functional food; and provision of customized services. In addition, the company engages in the pharmaceutical marketing business; and provision of U-healthcare solution that offers digitalized hospital solution and healthcare service for personnel. Further, it operates digital hospital in Thailand. Its healthcare network covers 30,000 …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
UBcare. Co reported revenue of 198B KRW in FY2025 versus 112B KRW in FY2021, a compound +15.3%/yr. Reported net income was 37.0B KRW in FY2025, compounding +29.1%/yr from FY2021.
Is 032620 fairly valued? → Check now
Similar stocks
10 more Software & IT Services stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| KINX, Inc 093320 | 116,000 KRW | 82,642 KRW | -29% |
| AfreecaTV Co 067160 | 45,500 KRW | 176,746 KRW | +288% |
| Hancom Inc 030520 | 18,560 KRW | 31,596 KRW | +70% |
| Gabia Inc 079940 | 29,400 KRW | 32,523 KRW | +11% |
| NEOWIZ 095660 | 17,160 KRW | 48,723 KRW | +184% |
| Webzen Inc 069080 | 10,920 KRW | 11,189 KRW | +2% |
| Wemade Max Co 101730 | 3,390 KRW | 6,249 KRW | +84% |
| GalaxiaMoneytree Co 094480 | 5,080 KRW | 3,778 KRW | -26% |
| DAEA TI Co 045390 | 2,865 KRW | 4,958 KRW | +73% |
| Polaris Office Corp 041020 | 2,965 KRW | 5,857 KRW | +98% |
Explore undervalued stocks
More undervalued Technology stocks →
Frequently asked questions
Is UBcare. Co (032620) undervalued?
What is the fair value of 032620?
What is the quality score of 032620?
What is the revenue of UBcare. Co (032620)?
What is the net profit margin of 032620?
Does UBcare. Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.